Health economics of asthma: assessing the value of asthma interventions.
The aim of this systematic review was to summarize and assess the quality of asthma intervention health economic studies from 2002 to 2007, compare the study findings with clinical management guidelines, and suggest avenues for future improvement of asthma health economic studies. Forty of the 177 studies met our inclusion criteria. We assessed the quality of studies using The Quality of Health Economic Studies validated instrument (total score range: 0-100). Six studies (15%) had quality category 2, 26 studies (65%) achieved quality category 3, and the remaining eight (20%) studies were scored as the highest quality level, category 4. Overall, the findings from this review are in line with the Global Initiative for Asthma clinical guidelines. Many asthma health economic studies lacked appropriate long term time horizons to match the chronic nature of the disease and suffered from using effectiveness measures that did not capture all disease related risks and benefits. We recommend that new asthma simulation models: be flexible to allow for long term time horizons, focus on using levels of asthma control in their structure, and estimate both long term asthma specific outcomes like well-controlled time as well as generic outcomes such as quality adjusted survival.
Campbell
J D
JD
Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA.
Spackman
D E
DE
Sullivan
S D
SD
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000494:pharmacology*; D001249:Asthma / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards
D018927:Anti-Asthmatic Agents